Search results
GSK. This is our US website, intended for US audiences only. Other market sites can be reached by visiting our location selector. © 2001-2024 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792.
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.
2 days ago · Emma Walmsley, Chief Executive Officer, GSK: "We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines. These, together with other R&D achievements, mean we have strengthened prospects for growth in all of our key therapeutic ...
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We prioritise innovation in vaccines and specialty medicines to prevent and treat disease. Download. GSK at a glance (PDF, 1.0MB) A focused biopharma company. People worldwide. 70k. Countries we operate in. >75.
Globally, our portfolio spans vaccines, specialty and general medicines, with R&D focused on science of the immune system, human genetics and advanced technologies. GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions.
Investors | GSK. 2024 First quarter announcement. We announced our first quarter 2024 results on Wednesday 1 May. Access our first quarter results and latest Annual Report below. Q1 2024 results Annual Report 2023 (PDF - 8.3MB) We’re confident in our future.
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore GSK in the US. Learn about our US businesses. Oncology. Leading the way to reimagine improved ways of engaging with people with cancer. Respiratory.
